About

Dr. Aaron G.L. Fletcher has served as a director of Actuate Therapeutics since April 2015 and is Chairperson of the Board and chair of its nominating and corporate governance committee. He is the founder and President of Bios Research, a healthcare-focused financial services firm he has led since 2012, and has worked as an independent consultant in the biotechnology and healthcare equity industry for over a decade. Through affiliated Bios Equity funds he is one of Actuate's largest shareholders. He currently serves on the boards of Cognition Therapeutics, Inc. and ONL Therapeutics, Inc., and has previously served on the boards of TFF Pharmaceuticals, Cue Biopharma, Lung Therapeutics, Rein Therapeutics (formerly Aileron Therapeutics), AbiliTech Medical and SWK Holdings. He is also a visiting professor at Dallas Baptist University and earned his Ph.D. in Biochemistry from Colorado State University.

Roles

Actuate Therapeutics, Inc.
Chairperson & Director · Current role
April 2015–present
Bios Research
Founder & President
2012 - present
Dallas Baptist University
Visiting Professor
2008 - present

External Roles

Cognition Therapeutics, Inc.
Director
2015 - present
ONL Therapeutics, Inc.
Director
2024 - present

Director Compensation

FY 2025
Fees earned or paid in cash
$78,000
ComponentAnnual cash retainers and committee/chair fees earned in 2025
Option awards
$103,995
ComponentAnnual stock option grant (15,000 shares, May 22, 2025), ASC 718 grant-date fair value
Total
$181,995

Also at Actuate Therapeutics, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.